Related Experiment Video
Updated: Aug 15, 2025
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction
Uğur Köktürk1, Hamdi Püşüroğlu1, Mustafa Umut Somuncu1
1Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.
Insights
High galectin-3 levels in ST-segment elevation myocardial infarction (STEMI) patients predict adverse cardiovascular events and heart failure, but not long-term mortality after primary percutaneous coronary intervention (PCI).
Area of Science:
- Cardiology
- Biomarkers
- Clinical Medicine
Background:
- ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular event.
- Galectin-3 is a potential biomarker for cardiovascular disease prognosis.
- Primary percutaneous coronary intervention (PCI) is a standard treatment for STEMI.
Purpose of the Study:
- To evaluate the short- and long-term prognostic value of serum galectin-3 levels.
- To assess galectin-3's association with adverse cardiovascular outcomes in STEMI patients undergoing primary PCI.
Main Methods:
- A cohort of 143 STEMI patients undergoing primary PCI was studied.
- Patients were stratified into high and low galectin-3 groups based on admission serum levels.
- Clinical outcomes were tracked for 2 years, including cardiovascular mortality, reinfarction, stroke, target vessel revascularization, heart failure, and re-hospitalization.
Main Results:
- The high galectin-3 group showed significantly higher rates of primary clinical outcomes at hospital discharge, 1 year, and 2 years.
- Elevated galectin-3 levels were associated with increased risk of heart failure and re-hospitalization at both 1 and 2 years.
- While galectin-3 predicted adverse events, left ventricular ejection fraction (LVEF) was the independent predictor of 2-year cardiovascular mortality, not galectin-3.
Conclusions:
- High serum galectin-3 levels are associated with short- and long-term adverse cardiovascular events, heart failure, and re-hospitalization in STEMI patients post-PCI.
- Galectin-3 is not an independent predictor of long-term cardiovascular mortality in this patient group.
- Galectin-3 may serve as a useful prognostic marker for short-term outcomes and complications following STEMI and primary PCI.
Abstract:
This study evaluated the short and long-term prognostic value of galectin-3 in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Patients (n = 143) were admitted with STEMI and followed up for 2 years. The study population was divided into high and low galectin-3 groups based on the admission median value of serum galectin-3. Primary clinical outcomes consisted of cardiovascular (CV) mortality, non-fatal reinfarction, stroke, and target vessel revascularization (TVR). CV events were recorded in hospital and at 1 and 2 years. The primary clinical outcomes (in-hospital, 1 year and 2 year) were significantly higher in the high galectin-3 group. (P = .008, P = .004, P = .002, respectively). High galectin-3 levels were also associated with heart failure development and re-hospitalization at both 1 year (P = .029, P = .009, respectively) and 2 years (P = .019, P = .036, respectively). According to Cox multivariate analysis, left ventricular ejection fraction (LVEF) was an independent predictor of 2-year cardiovascular mortality (P = .009), whereas galectin-3 was not (P = .291). Although high galectin-3 levels were not independent predictors of long-term CV mortality in patients with acute STEMI who underwent primary PCI, it was associated with short-term and long-term development of adverse CV events, heart failure, and re-hospitalization.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction